From AI Pioneer to Clinical Contender: Why AbCellera's Deep Pipeline and Cash Cushion Are Drawing Bullish Bets
Once a high-flying AI discovery platform, AbCellera Biologics is navigating a critical transition to a clinical-stage biotech. With a fortified balance sheet and key Phase 1 readouts on the horizon, some investors see a compelling, albeit risky, turnaround story taking shape.